Clinical trial • Phase III • Dermatology
TRIV-509 for Atopic dermatitis
Phase III trial of TRIV-509 for Atopic dermatitis. 48 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Atopic dermatitis
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 18-08-2025
- First CTIS Authorization Date
- 07-10-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 48
Eligibility
Recruits 48 No vulnerable populations selected (isVulnerablePopulationSelected = false); consent/assent handling not specified in the record..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected = false); consent/assent handling not specified in the record.
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 9
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 48
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-09-2025
- Latest Decision Or Authorization Date
- 21-01-2026
- Processing Time Days
- 121
- Number Of Sites
- 1
- Number Of Participants
- 48
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Dermatology
- Contact Person Name
- Robert Rissmann
- Contact Person Email
- rrissmann@chdr.nl
- Number Of Participants
- 48
Sponsor
Primary sponsor
- Full Name
- Triveni Bio Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- TRIV-509
Related trials
Other published trials that may interest you.